Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

Sperl J., Horvath G., Halota W., Arenas Ruiz-Tapiador J., Streinu-Cercel A., Jancoriene L., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.65, sa.6, ss.1112-1119, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.jhep.2016.07.050
  • Dergi Adı: JOURNAL OF HEPATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1112-1119
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background & Aims: Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV) infection; however, head-to-head comparisons are limited. The C-EDGE Head-2-Head Study compared the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) in patients with HCV infection.